BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLL

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Updates from the Phase I/II BRUIN study: pirtobrutinib in CLLПодробнее

BRUIN study: updated two-year subgroup analysis of pirtobrutinib for BTKi pre-treated MCLПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCLПодробнее

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

Pirtobrutinib resistance in CLL: early findingsПодробнее

Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN studyПодробнее

Phase I/II BRUIN update: efficacy of pirtobrutinib in R/R Waldenström's macroglobulinemiaПодробнее

BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLLПодробнее

Phase I/II BRUIN study: pirtobrutinib in patients intolerant to a covalent BTK inhibitorПодробнее

Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trialПодробнее

Updated results from the BRUIN study: pirtobrutinib in the treatment of MCLПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

Update on the Phase I/II BRUIN studyПодробнее

BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLLПодробнее

Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCLПодробнее

Pirtobrutinib Non-Covalent BTK Inhibitor for Chronic Lymphocytic Leukemia (CLL) - BRUIN StudyПодробнее

Latest updates from the Phase I/II BRUIN studyПодробнее